Suppr超能文献

基于多能干细胞的细胞治疗——前景与挑战。

Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges.

机构信息

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.

出版信息

Cell Stem Cell. 2020 Oct 1;27(4):523-531. doi: 10.1016/j.stem.2020.09.014.

Abstract

Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable diseases and injuries. Both ESCs and iPSCs are already being used in clinical trials. However, we continue to encounter practical issues that limit their use, including their inherent properties of tumorigenicity, immunogenicity, and heterogeneity. Here, I review two decades of research aimed at overcoming these three difficulties.

摘要

人类多能干细胞,如胚胎干细胞(ESCs)和诱导多能干细胞(iPSCs),为对抗难治性疾病和损伤的细胞疗法提供了前所未有的机会。ESCs 和 iPSCs 已经在临床试验中得到应用。然而,我们仍然遇到了限制它们使用的实际问题,包括它们固有的致瘤性、免疫原性和异质性。在这里,我回顾了过去 20 年旨在克服这三个困难的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验